Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Type 2 diabetes is a growing problem in Mexico. The present study was undertaken to evaluate the efficacy and safety of rosiglitazone 2 mg or 4 mg twice daily (bd) in combination with metformin 2.5 g/day in Mexican patients whose type 2 diabetes was inadequately controlled with metformin alone. Methods: This randomized, double‐blind, placebo‐controlled study was conducted at four centers in Mexico. A total of 116 patients were randomized to metformin 2.5 g/day plus placebo (n=39), metformin 2.5 g/day plus rosiglitazone 2 mg bd (n=37), or metformin 2.5 g/day plus rosiglitazone 4 mg bd (n=40) for 26 weeks. Results: Mean hemoglobin A 1c (HbA 1c) levels decreased significantly from baseline to Week 26 in the rosiglitazone 2 mg bd (−0.7%; p=0.0052) and 4 mg bd (−1.2%; p=0.0008) groups, but increased in the placebo group (+0.3%; p=0.2651). Mean fasting plasma glucose and fructosamine levels also improved significantly with metformin plus rosiglitazone therapy in a dose‐ordered manner compared with placebo (p≤0.0019 and p=0.0006, respectively). C‐peptide and immunoreactive insulin levels were decreased from baseline in both rosiglitazone groups. Although mean increases in total cholesterol, low‐density lipoprotein (LDL)‐cholesterol, and high‐density lipoprotein (HDL)‐cholesterol were observed in the rosiglitazone groups, the total cholesterol:HDL‐cholesterol ratio remained unchanged. The proportion of patients with one or more adverse events was similar across all three groups. There were no cases of hepatotoxicity. Conclusion: Addition of rosiglitazone 2 mg bd and 4 mg bd to metformin therapy improved glycemic control in Mexican patients whose type 2 diabetes was inadequately controlled by metformin alone. Furthermore, the combination of rosiglitazone plus metformin was well tolerated. Copyright © 2002 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · cited 1×
“Although monotherapy with conventional agents such as sulfonylurea, metformin, or insulin can be effective initially, up to 50% of patients need combination treatment to achieve glycemic control in the longer term [13].”
BackgroundMetabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Haffner, S. M., Ralph, D., Saad, M. F., Rewers, M., Mykkänen, L., Selby, J., Howard, G., Savage, P. J., Hamman, R. F., Wegenknecht, L. E., et al. (1996) · Diabetes · doi:10.2337/diab.45.6.742 · Cited by 536 · cited 1×
“A study in healthy patients suggested that, compared with non-Hispanic whites, Mexican Americans have greater insulin resistance and a higher acute insulin response – a strong predictor of type 2 diabetes [12].”
ResultCholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios
Kinosian, B., Glick, H., & Garland, G. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-9-199411010-00002 · Cited by 519
Epidemiologic aspects of lipid abnormalities
Criqui, M. H., & Golomb, B. A. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00212-5 · Cited by 158
Cited by
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss, R. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1496 · Cited by 756
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
Metformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes
I. S. Sobczak, A., A. Blindauer, C., & J. Stewart, A. (2019) · Nutrients · doi:10.3390/nu11092022 · Cited by 304
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300
“2% in 2 small, shortterm studies.(23,38) Twenty-seven of the trials (68%) were less than 1 year in duration.”
BackgroundA Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Chiquette, E., Ramirez, G., & DeFronzo, R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2097 · Cited by 291
Effect of thiazolidinediones on body weight in patients with diabetes mellitus
Fonseca, V. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.005 · Cited by 283
DeFronzo, R. A., Stonehouse, A. H., Han, J., & Wintle, M. E. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02941.x · Cited by 213
Metadata
- Authors
- Gómez‐Perez, F. J., Fanghänel‐Salmón, G., Antonio Barbosa, J., Montes‐Villarreal, J., Berry, R. A., Warsi, G., & Gould, E. M.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2002-03
- Volume
- 18
- Issue
- 2
- Pages
- 127-134
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2169775081
- Cited by
- 113
- References
- 8
- FWCI
- 8.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.